Differential expression of haptoglobin isoforms in chronic active hepatitis, cirrhosis and HCC related to HBV infection

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 871-877

  Sarvari, Jamal ^a,c,d   Mojtahedi, Zahra ^a   Kuramitsu, Yasuhiro ^d   Malek Hosseini, Seyed Ali ^b   Shahrabadi, Mahmoud Shamsi ^c   Ghaderi, Abbas ^a   Nakamura, Kazuyuki ^d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Haptoglobin 2 isoforms; Hepatitis B virus; Hepatocellular carcinoma; Liquid chromatography tandem mass spectrometry

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B; FICOLIN; HAPTOGLOBIN; HAPTOGLOBIN ALPHA CHAIN; HAPTOGLOBIN BETA CHAIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN DELTA CHAIN; IMMUNOGLOBULIN J CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; ISOPROTEIN; PREALBUMIN; RETINOL BINDING PROTEIN; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN;

ADULT; ARTICLE; CHRONIC ACTIVE HEPATITIS; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY;

EID: 79960291019     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.321     Document Type: Article

References (34)

1. Yang JD and Roberts LR: Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7: 448-458, 2010.
2. Elgouhari HM, Abu-Rajab Tamimi TI and Carey WD: Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis. Cleve Clin J Med 75: 881-889, 2008.
3. Merat S, Malekzadeh R, Rezvan H, Khatibian M: Hepatitis B in Iran. Arch Iran Med 3: 192-201, 2000.
4. Sherman M, Peltekian KM and Lee C: Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 22: 432-438, 1995.
5. Sheu JC, Sung JL, Chen DS, et al: Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 56: 660-666, 1985.
6. Hanash S: Disease proteomics. Nature 422: 226-232, 2003.
7. Pieper R, Gatlin CL, Makusky AJ, et al: The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 3: 1345-1364, 2003.
8. Feng JT, Liu YK, Song HY, et al: Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5: 4581-4588, 2005.
9. Sun Y, Zang Z, Xu X, et al: Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry. Int J Mol Sci 11: 1423-1433, 2010.
10. Shu H, Kang X, Guo K, et al: Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to α fetoprotein. Oncol Rep 24: 1271-1276, 2010.
11. He QY, Lau GK, Zhou Y, et al: Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. Proteomics 3: 666-674, 2003.
12. Yan JX, Wait R, Berkelman T, et al: A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21: 3666-3672, 2000.
13. Ura S, Honda M, Yamashita T, et al: Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49: 1098-1112, 2009.
14. Kim W, Oe Lim S, Kim JS, et al: Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res 9: 5493-5500, 2003.
15. Ahmed N, Barker G, Oliva KT, et al: Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 91: 129-140, 2004.
16. Ye B, Cramer DW, Skates SJ, et al: Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9: 2904-2911, 2003.
17. Ang IL, Poon TC, Lai PB, et al: Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res 5: 2691-2700, 2006.
18. Carter K and Worwood M: Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol 29: 92-110, 2007.
19. Di Bisceglie AM and Hoofnagle JH: Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 64: 2117-2120, 1989.
20. Chen CB, Su YC, Huang TT, et al: Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer. Clin Chim Acta 398: 48-52, 2008.
21. Shu H, Kang XN, Li M, et al: [Comparison of the serum proteomes of pathological stages during hepatocarcinogenesis]. Zhonghua Gan Zang Bing Za Zhi 17: 520-525, 2009.
22. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y and Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069-1075, 2001.
23. Ueki T, Kaneda Y, Tsutsui H, et al: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5: 226-230, 1999.
24. Rizzi F and Bettuzzi S: The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 17: R1-R17, 2010.
25. Kang YK, Hong SW, Lee H and Kim WH: Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol 35: 1340-1346, 2004.
26. Okano T, Kondo T, Kakisaka T, et al: Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 6: 3938-3948, 2006.
27. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M and Petito CK: Overexpression of clusterin in human breast carcinoma. Am J Pathol 157: 393-399, 2000.
28. Lau SH, Sham JS, Xie D, et al: Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25: 1242-1250, 2006.
29. Kuraya M, Ming Z, Liu X, Matsushita M and Fujita T: Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology 209: 689-697, 2005.
30. Andersen JD, Boylan KL, Xue FS, et al: Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 31: 599-610, 2010.
31. Greco M, Mitri MD, Chiriaco F, Leo G, Brienza E and Maffia M: Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett 283: 222-229, 2009.
32. Van Molle W, Denecker G, Rodriguez I, Brouckaert P, Vandenabeele P and Libert C: Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins. J Immunol 163: 5235-5241, 1999.
33. Durr R and Caselmann WH: Carcinogenesis of primary liver malignancies. Langenbecks Arch Surg 385: 154-161, 2000.
34. Dengler R, Eger G, Lottspeich F, Plewan A, Ogilvie A and Emmerich B: Proteolytic inactivation of alpha 1-proteinase inhibitor in vivo: detection, characterization and quantitation of the main fragment excreted in the urine of leukemia patients. Biol Chem Hoppe Seyler 373: 581-588, 1992.